InvestorsHub Logo
Followers 1
Posts 1
Boards Moderated 0
Alias Born 12/15/2014

Re: None

Monday, 12/15/2014 1:39:23 PM

Monday, December 15, 2014 1:39:23 PM

Post# of 48316
Valuation case for ONCS:

I am new to this board. I have been an investor of ONCS for over a year.

Seeing that there has been a lot of confusion as to the value of Immunopulse, I would like to provide a valuation case. It goes a bit into the science and the positioning of Immunopulse within the fast-moving immunotherapy space.

http://tinyurl.com/o4zztqf

Fundamentally, ONCS closest comparison is Tvec (acquired for $1B by Amgen in 2011). Both are being evaluated as combination therapies with Merck's PD1. Both have a very similar mechanism of action. The upcoming Immunopulse+PD1 trial has been significantly de-risked by Tvec's combination Yervoy trial results (mid-2014).

Best,
Justice
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ONCSQ News